Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8116 to 8130 of 8218 results

  1. NICE publishes single guideline for managing COVID-19

    One year on from the first national lockdown, NICE has today (23 March) published a single guideline for the management of COVID-19 in children and adults.

  2. NICE publishes updated clinical guideline on the diagnosis and management of atrial fibrillation

    NICE has today (27 April 2021) published its updated guideline on the diagnosis and management of atrial fibrillation (AF).

  3. NICE reaches important milestone in the UK's efforts to tackle antimicrobial resistance.

    Two new antimicrobial drugs are close to becoming the first to be made available as part of the UK’s innovative subscription-style payment model.

  4. Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund

    A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.

  5. Over 700 people a year could benefit from a new lung cancer drug

    An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced non-small-cell lung cancer (NSCLC) has been recommended by NICE and will be available to patients from today (Thursday, 14 April).

  6. Patients with rare blood disorders to receive new treatment option, says NICE

    In final guidance published today (20 May 2021), NICE has recommended ravulizumab (Ultomiris, Alexion Pharmaceuticals) as a treatment for paroxysmal nocturnal haemoglobinuria (PNH). Draft guidance published 19 May 2021 also recommends the treatment for atypical haemolytic uraemic syndrome (aHUS).

  7. NICE recommends 'game changing' histology independent cancer drug

    Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).

  8. NICE recommends first treatment for rare blood disorder

    People with a rare blood disorder have access to a new treatment following draft guidance from NICE.

  9. Avelumab not recommended as a maintenance treatment of urothelial cancer

    NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.

  10. Listening to patients and organisations to update NICE's quality standard on transition from children's to adults' services

    Melanie explains how the update to our quality standard on the transition from children’s to adults’ services will benefit young people, their families and carers.

  11. Make your voice heard on a NICE committee

    Home News Podcasts Make your voice heard on a NICE committee Podcasts 02 October 2024 Listen About this episode In this episode, we hear from

  12. Non-invasive weight loss procedure can be an option to treat obesity

    A procedure which reduces the size of the stomach by two-thirds to help people living with obesity to lose weight has been deemed safe and effective to be used in the NHS, NICE has said.

  13. More people could be offered genetic testing for genes linked to ovarian cancer

    A new draft NICE guideline for inherited ovarian cancer published today (15 September 2023), recommends more people are tested for genes linked to ovarian cancer.

  14. Adapted shoes recommended for people with severe osteoarthritis

    People with osteoarthritis who are eligible for knee surgery could be offered specially adapted shoes to help with their painful and stiff knees following a draft recommendation by NICE.

  15. Targeted treatment for rare form of aggressive lung cancer gets NICE approval

    Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer